SCHEMBL496713

SCHEMBL496713

Fc1ccccc1-c1nnc2c3ccccc3c(Cl)nn12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 2/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
TP53 P04637 2/20 0.45
MAPT P10636 2/20 0.45
POLB P06746 1/20 0.45
DCTPP1 Q9H773 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
NPC1 O15118 1/20 0.43
TSHR P16473 1/20 0.43
RAB9A P51151 1/20 0.43
HTT P42858 1/20 0.42
HSD11B1 P28845 1/20 0.42
PDE2A O00408 4/20 0.41
PDE10A Q9Y233 3/20 0.41
HPRT1 P00492 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
APAF1 O14727 1/20 0.40
HPGD P15428 1/20 0.40
RECQL P46063 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2830794 0.85 RXFP1 (0.62) RXFP1L3MBTL1TP53MAPTPOLB
SCHEMBL497344 0.84 RXFP1 (0.65) RXFP1L3MBTL1TP53MAPTPOLB
SCHEMBL2029201 0.82 RXFP1 (0.59) RXFP1L3MBTL1TP53MAPTPOLB
SCHEMBL497264 0.82 RXFP1 (0.59) RXFP1L3MBTL1TP53MAPTPOLB
SCHEMBL496605 0.82 RXFP1 (0.55) RXFP1L3MBTL1TP53MAPTPOLB
SCHEMBL7450997 0.81 RXFP1 (0.48) RXFP1L3MBTL1TP53MAPTPOLB
SCHEMBL496968 0.79 RXFP1 (0.58) RXFP1L3MBTL1TP53MAPTPOLB
SCHEMBL496580 0.79 RXFP1 (0.58) RXFP1L3MBTL1TP53MAPTPOLB
SCHEMBL497285 0.78 NPC1 (0.69) RXFP1L3MBTL1MAPTSMN1; SMN2NPC1
SCHEMBL5524673 0.74 RXFP1 (1.00) RXFP1L3MBTL1SMN1; SMN2NPC1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836207-B1 TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS NYCOMED GMBH (DE) 2012-10-10 EP disclosed
EP-1874775-B1 TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS NYCOMED GMBH (DE) 2012-10-10 EP disclosed
US-8106047-B2 (4-Methoxyphenyl)-[3-(4-methoxyphenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-amine; phosphodiesterase inhibitors; septic shock or vascular edema; neoangiogenesis or inflammatory disease NYCOMED GMBH (DE) 2012-01-31 US disclosed
US-20110136803-A1 Triazolophthalazines NYCOMED GMBH (DE) 2011-06-09 US disclosed
US-7851472-B2 Triazolophthalazines NYCOMED GMBH (DE) 2010-12-14 US disclosed
US-20100286140-A1 TRIAZOLOPHTHALAZINES NYCOMED GMBH (DE) 2010-11-11 US disclosed
EP-1791543-B1 TRIAZOLOPHTHALAZINES NYCOMED GMBH (DE) 2010-06-16 EP disclosed
US-7671050-B2 Triazolophthalazines NYCOMED GMBH (DE) 2010-03-02 US disclosed
US-20090005372-A1 Triazolophthalazines ALTANA PHARMA AG (DE) 2009-01-01 US disclosed
US-20080312225-A1 Triazolophthalazines NYCOMED GMBH (DE) 2008-12-18 US disclosed
US-20080280907-A1 Triazolophthalazines AALTANA PHARMA AG (DE) 2008-11-13 US disclosed
EP-1874775-A2 TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS Nycomed GmbH (DE) 2008-01-09 EP disclosed
EP-1836207-A2 TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS Nycomed GmbH (DE) 2007-09-26 EP disclosed
EP-1791543-A2 TRIAZOLOPHTHALAZINES Altana Pharma AG (DE) 2007-06-06 EP disclosed
WO-2006072612-A2 TRIAZOLOPHTHALAZINES AS PDE2- INHIBITORS NYCOMED GMBH (DE) 2006-07-13 WO disclosed
WO-2006072615-A2 TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS NYCOMED GMBH (DE) 2006-07-13 WO disclosed
WO-2006024640-A2 TRIAZOLOPHTHALAZINES ALTANA PHARMA AG (DE) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286140-A1 TRIAZOLOPHTHALAZINES PDE2A, PDE12, PDE3A RXFP1 223/4885L3MBTL1 4540/4885TP53 4660/4885
US-20080280907-A1 Triazolophthalazines PDE2A, PDE3A, PDE12 RXFP1 292/4885L3MBTL1 4111/4885TP53 4666/4885
US-20110136803-A1 Triazolophthalazines PDE2A, PDE3A, PDE12 RXFP1 292/4885L3MBTL1 4111/4885TP53 4666/4885
US-20090005372-A1 Triazolophthalazines PDE2A, PDE12, PDE3A RXFP1 223/4885L3MBTL1 4540/4885TP53 4660/4885
US-20080312225-A1 Triazolophthalazines PDE2A, PDE3A, PDE12 RXFP1 292/4885L3MBTL1 4111/4885TP53 4666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.